Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study

Table 1 Demographic comparison of patients in non-MT group and MT group

Index	Non-MT group (n = 87)	MT group (n = 71)	t/χ ²	P value
Age (Year, \(\overline{x}\) ± s)	60.28 ± 7.78	61.63 ± 9.30	0.869	0.386
Gender (N)			0.079	0.778
Man	52 (59.8%)	44 (62.0%)
Woman	35 (40.2%)	27 (38.0%)
Marital status (N)			1.348	0.246
Married	76 (87.4%)	66 (93.0%)
Non-married	11 (12.6%)	5 (7.0%)
Smoking history			0.799	0.372
Yes	58 (66.7%)	52 (73.2%)
No	29 (33.3%)	19 (26.8%)
Medical insurance			2.069	0.558
New rural cooperative	37 (42.5%)	26 (36.6%)
Residents	25 (28.7%)	21 (29.6%)
Employees	16 (18.4%)	19 (26.8%)
Self-pay	9 (10.4%)	5 (7.0%)
Pathological type (N)			0.842	0.175
Adenocarcinomas	65 (74.7%)	46 (64.8%)
Squamous	22 (25.3%)	25 (35.2%)
Clinical TNM stage (N)			0.589	0.443
IIIB	47 (54.0%)	34 (47.9%)
IV	40 (46.0%)	37 (52.1%)
Metastasis site (N)			0.955	0.917
Contralateral lung	31 (35.6%)	27 (38.0%)
Liver	14 (16.1%)	9 (12.7%)
Bone	18 (20.7%)	13 (18.3%)
Brain	17 (19.5%)	13 (18.3%)
Others	8 (9.2%)	9 (12.7%)
Distal metastasis (N)			1.313	0.252
1 ~ 2	55 (63.2%)	48 (67.6%)
≥ 3	32 (36.8%)	23 (32.4%)
PS score (N)			0.782	0.376
0 ~ 1	62 (71.3%)	55 (77.5%)
2	25 (28.7%)	16 (22.5%)
First-line chemotherapy drugs (N)			2.155	0.707
Vinorelbine + cisplatin/carboplatin	7	6
Taxol + cisplatin/carboplatin	9	6
Gemcitabine + cisplatin/carboplatin	26	15
Docetaxel + cisplatin/carboplatin	20	18
Pemetrexed + cisplatin/carboplatin	25	26
Antiangiogenic drugs (N)			0.574	0.750
Recombinant human vascular endostatin	8	6
Bevacizumab	11	12
No	68	53
Therapeutic efficacy			0.056	0.972
CR	7 (8.1%)	5 (7.0%)
PR	29 (33.3%)	24 (33.8%)
SD	51 (58.6%)	42 (59.2%)

MT, maintenance treatment; TNM, tumor, node, metastasis; PS, performance statue; CR, complete response; PR, partial response; SD, stable disease. P value of age was calculated by two-sided t-test, and the rest indexes were calculated by two-sided chi-square test

ISSN: 1477-7819